Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium.
Immunohistochemical study of bcl-2 protein immunoreactivity in human non-neoplastic mesothelium (44 cases) and in malignant mesothelioma (62 cases) using a murine monoclonal antibody (clone 124) showed cytoplasmic immunoreactivity for bcl-2 protein in five cases of malignant mesothelioma. Non-neoplastic mesothelium was not immunoreactive. Immunoreactivity for bcl-2 protein does not add useful prognostic information in malignant mesothelioma since survival times of bcl-2 positive and bcl-2 negative cases did not differ. Nevertheless, the detection of bcl-2 protein in malignant mesothelioma might be useful for the differentiation from reactive mesothelium.
Segers
K
K
Department of Pathology, University Hospital of Antwerp, University of Antwerp, Edegem, Belgium.
Ramael
M
M
Singh
S K
SK
Weyler
J
J
Van Meerbeeck
J
J
Vermeire
P
P
Van Marck
E
E
D004848:Epithelium / Q000737:chemistry; D006801:Humans; D007150:Immunohistochemistry; D008654:Mesothelioma / Q000737:chemistry* / Q000401:mortality; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D019253:Proto-Oncogene Proteins c-bcl-2; D015996:Survival Rate
D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2